Progyny (PGNY) Q3 Earnings and Revenues Beat Estimates

Core Insights - Progyny reported quarterly earnings of $0.45 per share, exceeding the Zacks Consensus Estimate of $0.39 per share, and showing an increase from $0.40 per share a year ago, resulting in an earnings surprise of +15.38% [1] - The company achieved revenues of $313.35 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.19% and increasing from $286.63 million year-over-year [2] - Progyny's stock has increased approximately 9.5% since the beginning of the year, while the S&P 500 has gained 15.6% [3] Earnings Outlook - The future performance of Progyny's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $0.39 on revenues of $303.26 million, and for the current fiscal year, it is $1.74 on revenues of $1.26 billion [7] Industry Context - The Medical Services industry, to which Progyny belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The correlation between near-term stock movements and earnings estimate revisions suggests that tracking these revisions can provide insights into Progyny's stock performance [5][6]